Recipharm deals boost revenues big time for Swedish CDMO

Recipharm saw its 2016 revenues powered by a string of deals, with sterile injectables providing a significant piece of that growth.

Swedish CDMO Recipharm has been on a buying and expansion binge for several years and saw it pay off with a significant jump in revenues last year.

The Stockholm-based contractor today reported that revenue grew 54% in the fourth quarter of 2016 to 1.33 billion Swedish kroner ($148.4 million) and 38% for the year to SEK 4.68 billion ($520.4 million).

“The fourth quarter marks the end of a transaction intensive year for Recipharm,” CEO Thomas Eldered said in a statement today. “With an increase in net sales of 54%, we recorded all time high sales for a quarter. Excluding acquisitions sales, it was still the highest ever for a fourth quarter with an increase of 17%, driven by the sterile liquids segment.”

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Recipharm’s sterile liquids unit saw 87% growth from 2016 acquisitions and a 59% jump from increased demand and new products, the company said.

Recipharm has been one of the most active buyers in what has been a surge of midsized and large CDMOs snapping up smaller operators around the world to gain skills and geographic reach. Just days ago Recipharm completed the second phase of a $200 million deal to buy operations in India, Sweden and the U.S. from India’s Kemwell that expanded both its drug development skills and API manufacturing.

The arrangement had the Swedish company pay about $85 million for operations in Sweden and the U.S. that included Kemwell’s drug development business in Research Triangle Park, North Carolina. Last week it concluded the second part of the acquisition with a $118 million buyout of Kemwell’s API business in India. The company said that portion of the buyout will complement its $105 million acquisition in 2015 of a controlling stake in Indian sterile injectables CMO, Nitin Lifesciences.


Suggested Articles

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.